Guangzhou Baiyunshan Pharmaceutical Holdings

600332.SS

Guangzhou, China· Est. 1896

gzbys.com

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

600332.SS · Stock Price

CNY 22.70-3.81 (-14.37%)

Market Cap: $5.4B

Historical price data

Overview

Baiyunshan's mission is to leverage its dual heritage in Traditional Chinese Medicine and modern pharmaceuticals to become a global leader in integrated healthcare. Its key achievements include establishing one of China's most recognized pharmaceutical brands, building a diversified portfolio with numerous blockbuster TCM formulas and generic drugs, and operating a massive, vertically integrated supply chain. The company's strategy focuses on deepening its TCM scientific validation, expanding its innovative and generic chemical drug pipeline, and capitalizing on supportive national healthcare policies to drive sustainable growth.

OncologyCardiovascular & MetabolicRespiratoryAnti-infectiveNeurological/CNSGeneral Health & Wellness

Technology Platform

A dual-platform strategy integrating a modernized, evidence-based Traditional Chinese Medicine (TCM) system with a full-spectrum Western-style chemical and biological pharmaceutical development and manufacturing platform.

Pipeline

3 drugs in pipeline

Drug	Indication	Stage
placebo of oseltamivir phosphate + oseltamivir phosphate + B...	Influenza	Approved
Huatuo Zaizao Pills	Ischemic Stroke	Approved
Fufangdanshen Tablets + Placebo	Vascular Dementia	Phase 2

Opportunities

The company is a prime beneficiary of China's 'Healthy China 2030' policy, which promotes TCM integration and modernization.

Significant opportunities exist in expanding healthcare access in lower-tier cities, exporting validated TCM products globally, and consolidating generic drug market share through national volume-based procurement tenders.

Risk Factors

Major risks include exposure to stringent Chinese drug pricing reforms (Volume-Based Procurement) that can cause sudden price erosion, the operational complexity of managing a vast integrated conglomerate, and a potential innovation gap compared to pure-play R&D biopharma firms.

Quality control incidents pose a severe reputational threat.

Competitive Landscape

Baiyunshan competes in TCM with historical peers like Tasly and Yunnan Baiyao, and in generics with giants like Jiangsu Hengrui. Its unique, vertically integrated 'manufacturing + distribution + retail' model provides a defensible moat, insulating it from direct competition across all segments and allowing it to capture value at multiple points in the healthcare chain.